Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

101.16 -1.83 (-1.78%)
Streaming Delayed Price Updated: 2:41 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
News headline image
Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Natera (NASDAQ:NTRA) and the... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Top S&P500 movers in Tuesday's pre-market session ↗
Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
INCYTE CORP (NASDAQ:INCY) Presents a Compelling Case for Value Investors ↗
INCYTE CORP (INCY) is a strong value investing candidate with a low P/E ratio, a healthy balance sheet, and solid profitability, suggesting it's an undervalued stock. 
Via Chartmill
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals. 
Via The Motley Fool
News headline image
Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗
While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate. 
Via Benzinga
Topics Artificial Intelligence
News headline image
1 Mid-Cap Stock to Consider Right Now and 2 We Turn Down
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
News headline image
Peering Into Incyte Corp's Recent Short Interest ↗
 
Via Benzinga
News headline image
Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at immuno-oncology stocks, starting with... 
Via StockStory
Topics Artificial Intelligence
News headline image
Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks
Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Topics Economy Supply Chain
News headline image
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
From Incyte
Via Business Wire
News headline image
Incyte (INCY): Buy, Sell, or Hold Post Q3 Earnings?
The past six months have been a windfall for Incyte’s shareholders. The company’s stock price has jumped 78.7%, setting a new 52-week high of $106.50 per share. This was partly due to its solid... 
Via StockStory
News headline image
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
The 5 Most Interesting Analyst Questions From Incyte’s Q3 Earnings Call
Incyte’s third quarter saw revenue and profit surpass Wall Street’s expectations, yet the market responded negatively. Management identified robust demand for key drugs Jakafi and Opzelura, alongside... 
Via StockStory
Topics Earnings
News headline image
Stay informed with the top movers within the S&P500 index on Monday. ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday. 
Via Chartmill
News headline image
Kenvue, IDEXX Laboratories, Freshpet And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
These S&P500 stocks have an unusual volume in today's session ↗
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below. 
Via Chartmill
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of... 
Via StockStory
News headline image
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms ↗
Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook. 
Via Benzinga
Topics Intellectual Property
News headline image
These S&P500 stocks have an unusual volume in today's session ↗
Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below. 
Via Chartmill
News headline image
Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday? ↗
Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech earnings. 
Via Benzinga
Topics Economy
News headline image
Why Incyte (INCY) Stock Is Trading Lower Today
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results. 
Via StockStory
News headline image
Incyte (INCY) Q3 2025 Earnings Call Transcript ↗
Incyte (INCY) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views ↗
The company delivered significantly better-than-expected third-quarter sales and earnings, but shares took a premarket hit. 
Via Investor's Business Daily
Topics Government
News headline image
Incyte Corp (NASDAQ:INCY) Reports Strong Q3 2025 Earnings, Beating Estimates ↗
Incyte (INCY) Q3 2025 earnings beat expectations with $1.37B revenue and $2.26 EPS. Driven by Jakafi and Opzelura growth, the company also raised its full-year 2025 guidance. 
Via Chartmill
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.